Imaging epidermal growth factor receptor expression in vivo: Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe

Parmeswaran Diagaradjane, Jacobo M. Orenstein-Cardona, Norman E. Colón-Casasnovas, Amit Deorukhkar, Shujun Shentu, Norihito Kuno, David L. Schwartz, Juri G. Gelovani, Sunil Krishnan

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR. Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD. Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx (∼3 min), clearance (∼60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at ∼60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD. Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobemay permit quantifiable and repetitive imaging of EGFR expression.

Original languageEnglish (US)
Pages (from-to)731-741
Number of pages11
JournalClinical Cancer Research
Volume14
Issue number3
DOIs
StatePublished - Feb 1 2008

Fingerprint

Quantum Dots
Epidermal Growth Factor Receptor
Pharmacokinetics
Epidermal Growth Factor
Neoplasms
Fluorescence
Optical Imaging
Sulfhydryl Compounds
Heterografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diagaradjane, P., Orenstein-Cardona, J. M., Colón-Casasnovas, N. E., Deorukhkar, A., Shentu, S., Kuno, N., ... Krishnan, S. (2008). Imaging epidermal growth factor receptor expression in vivo: Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clinical Cancer Research, 14(3), 731-741. https://doi.org/10.1158/1078-0432.CCR-07-1958

Imaging epidermal growth factor receptor expression in vivo : Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. / Diagaradjane, Parmeswaran; Orenstein-Cardona, Jacobo M.; Colón-Casasnovas, Norman E.; Deorukhkar, Amit; Shentu, Shujun; Kuno, Norihito; Schwartz, David L.; Gelovani, Juri G.; Krishnan, Sunil.

In: Clinical Cancer Research, Vol. 14, No. 3, 01.02.2008, p. 731-741.

Research output: Contribution to journalArticle

Diagaradjane, P, Orenstein-Cardona, JM, Colón-Casasnovas, NE, Deorukhkar, A, Shentu, S, Kuno, N, Schwartz, DL, Gelovani, JG & Krishnan, S 2008, 'Imaging epidermal growth factor receptor expression in vivo: Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe', Clinical Cancer Research, vol. 14, no. 3, pp. 731-741. https://doi.org/10.1158/1078-0432.CCR-07-1958
Diagaradjane, Parmeswaran ; Orenstein-Cardona, Jacobo M. ; Colón-Casasnovas, Norman E. ; Deorukhkar, Amit ; Shentu, Shujun ; Kuno, Norihito ; Schwartz, David L. ; Gelovani, Juri G. ; Krishnan, Sunil. / Imaging epidermal growth factor receptor expression in vivo : Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 3. pp. 731-741.
@article{c378e528a7c64c9682e36541f2c8b1a4,
title = "Imaging epidermal growth factor receptor expression in vivo: Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe",
abstract = "Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR. Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD. Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx (∼3 min), clearance (∼60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at ∼60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD. Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobemay permit quantifiable and repetitive imaging of EGFR expression.",
author = "Parmeswaran Diagaradjane and Orenstein-Cardona, {Jacobo M.} and Col{\'o}n-Casasnovas, {Norman E.} and Amit Deorukhkar and Shujun Shentu and Norihito Kuno and Schwartz, {David L.} and Gelovani, {Juri G.} and Sunil Krishnan",
year = "2008",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-07-1958",
language = "English (US)",
volume = "14",
pages = "731--741",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Imaging epidermal growth factor receptor expression in vivo

T2 - Pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe

AU - Diagaradjane, Parmeswaran

AU - Orenstein-Cardona, Jacobo M.

AU - Colón-Casasnovas, Norman E.

AU - Deorukhkar, Amit

AU - Shentu, Shujun

AU - Kuno, Norihito

AU - Schwartz, David L.

AU - Gelovani, Juri G.

AU - Krishnan, Sunil

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR. Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD. Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx (∼3 min), clearance (∼60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at ∼60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD. Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobemay permit quantifiable and repetitive imaging of EGFR expression.

AB - Purpose: To develop and validate an optical imaging nanoprobe for the discrimination of epidermal growth factor (EGF) receptor (EGFR)-overexpressing tumors from surrounding normal tissues that also expresses EGFR. Experimental Design: Near-infrared (NIR) quantum dots (QD) were coupled to EGF using thiol-maleimide conjugation to create EGF-QD nanoprobes. In vitro binding affinity of these nanoprobes and unconjugated QDs was evaluated in a panel of cell lines, with and without anti-EGFR antibody pretreatment. Serial optical imaging of HCT116 xenograft tumors was done after systemic injection of QD and EGF-QD. Results: EGF-QD showed EGFR-specific binding in vitro. In vivo imaging showed three distinct phases, tumor influx (∼3 min), clearance (∼60 min), and accumulation (1-6 h), of EGF-QD nanoprobes. Both QD and EGF-QD showed comparable nonspecific rapid tumor influx and clearance followed by attainment of an apparent dynamic equilibrium at ∼60 min. Subsequently (1-6 h), whereas QD concentration gradually decreased in tumors, EGF-QDs progressively accumulated in tumors. On delayed imaging at 24 h, tumor fluorescence decreased to near-baseline levels for both QD and EGF-QD. Ex vivo whole-organ fluorescence, tissue homogenate fluorescence, and confocal microscopic analyses confirmed tumor-specific accumulation of EGF-QD at 4 h. Immunofluorescence images showed diffuse colocalization of EGF-QD fluorescence within EGFR-expressing tumor parenchyma compared with patchy perivascular sequestration of QD. Conclusion: These results represent the first pharmacokinetic characterization of a robust EGFR imaging nanoprobe. The measurable contrast enhancement of tumors 4 h after systemic administration of EGF-QD and its subsequent normalization at 24 h imply that this nanoprobemay permit quantifiable and repetitive imaging of EGFR expression.

UR - http://www.scopus.com/inward/record.url?scp=38949102704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949102704&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-1958

DO - 10.1158/1078-0432.CCR-07-1958

M3 - Article

C2 - 18245533

AN - SCOPUS:38949102704

VL - 14

SP - 731

EP - 741

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -